Table 3.
Subgroup analysis of the HR (95% CI) for incident diabetes by hs-cTnT group
| ≤5 ng/L | 6–8 ng/L | 9–13 ng/L | ≥14 ng/L | P for trend | P for interaction* | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Men | ||||||
| Model 1 | Reference | 0.94 (0.79–1.13) | 1.03 (0.84–1.27) | 1.30 (1.02–1.65) | 0.088 | 0.148 |
| Model 2 | Reference | 0.91 (0.76–1.09) | 1.06 (0.87–1.30) | 1.20 (0.94–1.54) | 0.156 | 0.172 |
| Women | ||||||
| Model 1 | Reference | 0.99 (0.83–1.18) | 1.27 (1.01–1.59) | 0.88 (0.57–1.35) | 0.367 | – |
| Model 2 | Reference | 0.93 (0.78–1.11) | 1.20 (0.96–1.50) | 0.79 (0.51–1.22) | 0.930 | – |
| Race | ||||||
| White | ||||||
| Model 1 | Reference | 0.94 (0.81–1.08) | 1.14 (0.96–1.36) | 1.20 (0.95–1.51) | 0.096 | 0.393 |
| Model 2 | Reference | 0.90 (0.77–1.04) | 1.05 (0.89–1.26) | 1.12 (0.88–1.42) | 0.458 | 0.364 |
| Black | ||||||
| Model 1 | Reference | 1.05 (0.82–1.33) | 1.08 (0.80–1.46) | 1.25 (0.85–1.83) | 0.289 | – |
| Model 2 | Reference | 0.98 (0.77–1.25) | 1.13 (0.83–1.52) | 1.10 (0.75–1.61) | 0.483 | – |
| Age | ||||||
| <65 years | ||||||
| Model 1 | Reference | 1.00 (0.86–1.18) | 1.32 (1.09–1.62) | 1.21 (0.91–1.62) | 0.018 | 0.202 |
| Model 2 | Reference | 0.94 (0.80–1.10) | 1.34 (1.10–1.64) | 1.22 (0.91–1.62) | 0.025 | 0.132 |
| ≥65 years | ||||||
| Model 1 | Reference | 0.96 (0.78–1.17) | 0.99 (0.79–1.23) | 1.26 (0.95–1.67) | 0.311 | – |
| Model 2 | Reference | 0.92 (0.76–1.13) | 0.92 (0.73–1.15) | 0.99 (0.74–1.32) | 0.645 | – |
| Statin use | ||||||
| Yes | ||||||
| Model 1 | Reference | 0.64 (0.42–0.97) | 1.15 (0.76–1.72) | 0.63 (0.31–1.25) | 0.495 | 0.174 |
| Model 2 | Reference | 0.73 (0.48–1.11) | 1.13 (0.76–1.70) | 0.78 (0.39–1.55) | 0.817 | 0.228 |
| No | ||||||
| Model 1 | Reference | 1.03 (0.91–1.17) | 1.14 (0.97–1.34) | 1.34 (1.09–1.66) | 0.006 | – |
| Model 2 | Reference | 0.97 (0.85–1.11) | 1.13 (0.96–1.32) | 1.20 (0.97–1.48) | 0.069 | – |
| Hypercholesterolemia | ||||||
| Yes | ||||||
| Model 1 | Reference | 0.64 (0.44–0.92) | 1.10 (0.77–1.57) | 0.81 (0.44–1.47) | 0.656 | 0.046 |
| Model 2 | Reference | 0.71 (0.50–1.03) | 0.98 (0.69–1.40) | 0.97 (0.53–1.76) | 0.689 | 0.104 |
| No | ||||||
| Model 1 | Reference | 1.05 (0.92–1.20) | 1.14 (0.97–1.34) | 1.33 (1.07–1.64) | 0.008 | – |
| Model 2 | Reference | 0.99 (0.86–1.13) | 1.13 (0.95–1.33) | 1.18 (0.95–1.46) | 0.085 | – |
| Hypertension | ||||||
| Yes | ||||||
| Model 1 | Reference | 1.01 (0.86–1.19) | 1.17 (0.97–1.41) | 1.08 (0.85–1.38) | 0.190 | 0.116 |
| Model 2 | Reference | 0.95 (0.81–1.12) | 1.13 (0.94–1.36) | 1.00 (0.78–1.29) | 0.523 | 0.387 |
| No | ||||||
| Model 1 | Reference | 0.92 (0.75–1.12) | 1.05 (0.81–1.36) | 1.71 (1.22–2.41) | 0.071 | – |
| Model 2 | Reference | 0.88 (0.72–1.07) | 1.08 (0.83–1.39) | 1.46 (1.03–2.07) | 0.199 | – |
| BMI | ||||||
| <25 kg/m2 | ||||||
| Model 1 | Reference | 0.87 (0.61–1.22) | 0.89 (0.55–1.45) | 0.97 (0.48–1.99) | 0.579 | <0.001 |
| Model 2 | Reference | 0.83 (0.59–1.18) | 0.89 (0.54–1.45) | 0.89 (0.43–1.84) | 0.449 | <0.001 |
| 25–30 kg/m2 | ||||||
| Model 1 | Reference | 1.14 (0.93–1.40) | 1.15 (0.89–1.48) | 1.46 (1.04–2.05) | 0.032 | – |
| Model 2 | Reference | 1.08 (0.88–1.33) | 1.07 (0.83–1.39) | 1.41 (1.00–1.98) | 0.097 | – |
| ≥30 kg/m2 | ||||||
| Model 1 | Reference | 0.94 (0.79–1.12) | 1.21 (0.99–1.48) | 1.19 (0.91–1.55) | 0.082 | – |
| Model 2 | Reference | 0.89 (0.74–1.06) | 1.21 (0.99–1.48) | 1.03 (0.78–1.34) | 0.337 | – |
Model 1: age, race-center, sex, total cholesterol, HDL-C, LDL-C, triglycerides, BMI, eGFR, systolic blood pressure, blood pressure–lowering medication use, smoking status, cholesterol-lowering medication use, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level; model 2: model 1 plus fasting glucose.
*P value for interaction within the respective subgroup, where applicable.